GleamWall
中文EN

ALLO Allogene Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1737287 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-26.7%
TTM net income YoY22.1%
TTM EPS YoY36.8%
Revenue 3-yr CAGR-91.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,241,813.6%
Net margin-1,170,863.6%
FCF margin-913,609.1%
EBITDA margin-1,179,818.2%

Returns

ROE-55.1%
ROA-43.2%
ROIC (approx.)-57.1%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets23.1%
Debt / equity0.00x
Current ratio8.54x
Interest coverage-1,509.39x

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue3,154.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$4.64M—$0$0$0$0$0
R&D expense$41.93M$30.72M$32.00M$28.63M$31.16M$40.16M$50.20M$44.97M
SG&A expense$12.86M$20.84M$14.09M$13.77M$13.74M$14.28M$14.99M$15.52M
Operating income-$54.79M-$46.92M-$46.09M-$42.40M-$44.90M-$56.82M-$65.19M-$60.49M
Interest expense$379,000$343,000$300,000$313,000$344,000$268,000$150,000$81,000
Net income-$50.37M-$42.68M-$42.61M-$38.81M-$41.40M-$50.94M-$59.73M-$59.94M
EBITDA-$52.21M-$44.27M-$43.22M-$39.35M-$41.80M-$53.71M-$62.09M-$57.26M
EPS (basic)-0.15-0.13-0.18—-0.19-0.23-0.28—
EPS (diluted)-0.15-0.13-0.18—-0.19-0.23-0.28—
Weighted avg. shares (diluted)346.09M328.93M240.29M—222.04M218.93M215.36M—
Balance sheet
Cash & equivalents$29.27M$38.63M$30.31M$51.69M$48.11M$62.62M$52.75M$85.51M
Short-term investments$263.69M$293.98M$236.58M$198.52M$214.38M$220.79M$237.59M$217.26M
Current assets$299.83M$340.00M$273.29M$257.75M$260.72M$282.65M$291.58M$303.39M
PP&E, net$64.82M$67.38M$70.02M$72.84M$75.90M$78.86M$82.99M$86.06M
Total assets$511.32M$550.09M$395.96M$415.90M$439.77M$470.59M$507.98M$548.71M
Current liabilities$38.50M$31.73M$28.33M$32.51M$31.83M$31.68M$30.02M$35.52M
Total liabilities$118.77M$113.92M$117.08M$123.36M$124.44M$126.03M$122.59M$126.53M
Shareholders' equity$392.55M$436.18M$278.88M$292.54M$315.33M$344.56M$385.39M$422.18M
Shares outstanding346.28M345.35M244.82M229.41M223.16M220.13M218.60M212.21M
Cash flow statement
Operating cash flow-$36.12M-$32.00M-$12.91M-$27.60M-$29.69M-$39.03M-$52.93M-$36.70M
Capital expenditure$25,000$150,000$9,000$0$243,000$44,000$99,000$257,000
Free cash flow-$36.14M-$32.15M-$12.92M-$27.60M-$29.93M-$39.07M-$53.03M-$36.95M
Investing cash flow$26.12M-$147.56M-$29.59M$33.61M$11.94M$43.84M$6.18M$54.93M
Financing cash flow$646,000$187.87M$21.12M$7.86M$3.24M$5.07M$13.99M$5.74M
Depreciation & amortization$2.59M$2.65M$2.87M$3.06M$3.10M$3.11M$3.10M$3.23M
Stock-based compensation$7.03M$12.44M$8.27M$8.13M$8.65M$8.69M$12.18M$12.87M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.